Status:
COMPLETED
Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting Conditions
Lead Sponsor:
Sandoz
Conditions:
Chronic Hepatitis C
Eligibility:
FEMALE
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to demonstrate the relative bioavailability of Ribavirin 200 capsules and Rebetol 200 mg capsules in females under non-fasting conditions.
Eligibility Criteria
Inclusion
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Exclusion
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
Key Trial Info
Start Date :
April 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2001
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00959933
Start Date
April 1 2001
End Date
May 1 2001
Last Update
March 28 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.